ArticleWorld journal of surgical oncology2026
Mesopancreas excision in pancreatic ductal adenocarcinoma: recurrence patterns - a single-arm descriptive study.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMesopancreas excision has emerged as a critical component of pancreaticoduodenectomy for pancreatic ductal adenocarcinoma (PDAC), potentially improving oncological outcomes. However, comprehensive data on recurrence patterns following mesopancreas excision remain limited.
objectiveTo analyze recurrence patterns in patients with PDAC who underwent pancreaticoduodenectomy with mesopancreas excision at a tertiary care center in Egypt.
methodsThis single-arm, single-center, retrospective descriptive cohort study with prospective follow-up included 86 patients with PDAC who underwent pancreaticoduodenectomy with complete mesopancreas excision at Liver and GIT Hospital, Minia University, between February 2018 and February 2024. Patients were followed for a minimum of 24 months, with data collection concluding in February 2026. Data collected included demographics, tumor characteristics, surgical outcomes, pathological findings, and recurrence patterns. The primary outcome was disease recurrence; secondary outcomes included recurrence-free survival (RFS), overall survival (OS), and patterns of recurrence distribution.
resultsOf 86 patients (mean age 58.4 ± 9.2 years, 61.6% male), R0 resection was achieved in 73 patients (84.9%). During follow-up, 52 patients (60.5%) developed recurrence at a median of 11.3 months. Local recurrence occurred in 18 patients (34.6%), distant metastases in 21 patients (40.4%), and combined recurrence in 13 patients (25.0%). The liver was the most common site of distant recurrence, involved in 42.3% of all recurrent cases, followed by lungs (23.1%) and peritoneum (19.2%). Median RFS was 13.2 months (95% CI: 10.8-15.6), and median OS was 18.7 months (95% CI: 16.3-21.1). Lymph node positivity (HR 2.34, p = 0.003), poor differentiation (HR 1.89, p = 0.012), and elevated CA19-9 (HR 1.67, p = 0.028) were independent predictors of recurrence.
conclusionDespite complete mesopancreas excision, PDAC demonstrates high recurrence rates with a predominant distant metastatic pattern. Early systemic therapy and intensive surveillance protocols may be warranted for high-risk patients. This study describes the recurrence patterns following complete mesopancreas excision; however, due to the absence of a concurrent control group and the exclusion of patients requiring vascular resection/reconstruction, any superiority in the observed R0 resection rate cannot be directly attributed to the surgical technique itself, and prospective randomized controlled trials remain necessary to establish the oncological benefit of complete mesopancreas excision over standard pancreaticoduodenectomy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.